Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Apr 15;2(4):179-182.
doi: 10.1002/iju5.12070. eCollection 2019 Jul.

Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report

Masashi Oshima  1 , Shozaburou Mayumi  1 , Kai Yazaki  1 , Yuuki Nakamura  1 , Tsuzumi Konishi  1 , Kimitoshi Saito  1 , Satoshi Washino  1 , Tomoaki Miyagawa  1
Affiliations
Case Reports

Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report

Masashi Oshima et al. IJU Case Rep. .

Abstract

Introduction: Tumor lysis syndrome is a rare and potentially fatal complication of oncological treatment. It is characterized by biochemical changes associated with the rapid lysis of malignant cells, usually after chemotherapy. Tumor lysis syndrome is typically noted in patients with hematological malignancies, and it rarely occurs in patients with solid tumors.

Case presentation: We report a case of tumor lysis syndrome after cabazitaxel administration for metastatic castration-resistant prostate cancer. To our knowledge, tumor lysis syndrome after cabazitaxel therapy has not been reported previously. The patient was a 77-year-old man who developed clinical tumor lysis syndrome after a single dose of cabazitaxel for metastatic castration-resistant prostate cancer. He was treated with hydration and the recombinant uricolytic agent rasburicase, and his condition improved.

Conclusion: It is extremely important to assess the risk factors for tumor lysis syndrome and to perform active prevention procedures in order to avoid fatal outcomes. It may be beneficial to use rasburicase in patients with established tumor lysis syndrome.

Keywords: cabazitaxel; castration‐resistant prostate cancer; chemotherapy; prostate cancer; tumor lysis syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a–c,e) CT of the abdomen. (a) Low‐defined prostate tumor (*). (b) Multiple tumor burden in the liver (*). (c) Pelvic lymphadenopathy (*). (d) Bone scan. Multiple bone metastases. (e) Hemorrhage from liver metastases (*).
Figure 2
Figure 2
Proposed evaluation for the risk of TLS and its prevention among patients with solid tumors.
See this image and copyright information in PMC

References

    1. Kelly KM, Lange B. Oncologic emergencies. Pediatr. Clin. North Am. 1997; 44: 809–30. - PubMed
    1. Brinton T, Yousuf T, Steinecker G, Rydel J. A case of tumor lysis syndrome in a patient with pancreatic adenocarcinoma treated with low‐dose gemcitabine. Ochsner J. 2015; 15: 455–6. - PMC - PubMed
    1. Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6: 68–76. - PMC - PubMed
    1. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother. Pharmacol. 2003; 51: 187–92. - PubMed
    1. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ. Tumor lysis syndrome. Semin. Thromb. Hemost. 2007; 33: 397–407. - PubMed

Publication types

LinkOut - more resources